Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fosaprepitant on Evoked Potentials
NCT03197064Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Countries
- 1
- Sponsor
- Stanford University
- Modality
- Small Molecules
- Drugs
- fosaprepitant
- Conditions
- postoperative nausea and vomiting (PONV)
01
Overview
Phase 4, open-label, single-arm trial of fosaprepitant in postoperative nausea and vomiting (PONV), sponsored by Stanford University. Primary endpoints: Somatosensory Evoked Potentials Extremity Amplitude (Left Upper Extremity), Somatosensory Evoked Potentials Extremity Amplitude (Right Upper Extremity) and 3 more. Started Jan 2018; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Fosaprepitant
Patients receive Fosaprepitant 150 mg IV
03
Who it enrols
Patients undergoing a surgical procedure requiring general anesthesia where neuromonitoring with somatosensory and motor evoked potentials is requested.
04
Endpoints
Primary
Somatosensory Evoked Potentials Extremity Amplitude (Left Upper Extremity)
Somatosensory Evoked Potentials Extremity Amplitude (Right Upper Extremity)
Somatosensory Evoked Potentials Extremity Amplitude (Left Lower Extremity)
Somatosensory Evoked Potentials Extremity Amplitude (Right Lower Extremity)
Motor Evoked Potentials Amplitude (Left Upper Extremity)
Beyond the preview
Go deeper on NCT03197064.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197064.